Is LBRX or PALI more profitable?

LB Pharmaceuticals' return on equity of -25.92% beat Palisade Bio's return on equity. Company Net Margins Return on Equity Return on Assets LB Pharmaceuticals N/A -25.92% -24.68% Palisade Bio N/A -33.47% -31.79%

Does the media favor LBRX or PALI?

In the previous week, Palisade Bio had 8 more articles in the media than LB Pharmaceuticals. MarketBeat recorded 9 mentions for Palisade Bio and 1 mentions for LB Pharmaceuticals. LB Pharmaceuticals' average media sentiment score of 1.67 beat Palisade Bio's score of 0.20 indicating that LB Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LB Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Palisade Bio 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer XERS or PALI?

In the previous week, Palisade Bio had 6 more articles in the media than Xeris Biopharma. MarketBeat recorded 9 mentions for Palisade Bio and 3 mentions for Xeris Biopharma. Xeris Biopharma's average media sentiment score of 0.68 beat Palisade Bio's score of 0.20 indicating that Xeris Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xeris Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Palisade Bio 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, HROW or PALI?

Harrow has higher revenue and earnings than Palisade Bio. Harrow is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Harrow $275.59M 4.57 -$5.14M -$1.00 N/A Palisade Bio $250K 1,115.33 -$16.78M -$0.48 N/A

Is HROW or PALI more profitable?

Palisade Bio has a net margin of 0.00% compared to Harrow's net margin of -13.51%. Palisade Bio's return on equity of -33.47% beat Harrow's return on equity. Company Net Margins Return on Equity Return on Assets Harrow -13.51% -38.00% -3.37% Palisade Bio N/A -33.47% -31.79%

Does the media refer more to HROW or PALI?

In the previous week, Palisade Bio had 8 more articles in the media than Harrow. MarketBeat recorded 9 mentions for Palisade Bio and 1 mentions for Harrow. Palisade Bio's average media sentiment score of 0.20 beat Harrow's score of 0.00 indicating that Palisade Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harrow 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Palisade Bio 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is PALI or SPTX more profitable?

Seaport Therapeutics' return on equity of 0.00% beat Palisade Bio's return on equity. Company Net Margins Return on Equity Return on Assets Palisade Bio N/A -33.47% -31.79% Seaport Therapeutics N/A N/A N/A

Do analysts prefer CALT or PALI?

Palisade Bio has a consensus target price of $9.83, indicating a potential upside of 514.58%. Given Palisade Bio's stronger consensus rating and higher possible upside, analysts clearly believe Palisade Bio is more favorable than Calliditas Therapeutics AB (publ). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Palisade Bio 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.00

Palisade Bio (PALI) Competitors

$1.60 -0.09 (-5.33%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$1.62 +0.02 (+1.25%)

As of 05:54 AM Eastern

Compare

PALI vs. LBRX, XERS, HROW, SPTX, and CALT

Should you buy Palisade Bio stock or one of its competitors? Palisade Bio's main competitors and comparable companies include LB Pharmaceuticals (LBRX), Xeris Biopharma (XERS), Harrow (HROW), Seaport Therapeutics (SPTX), and Calliditas Therapeutics AB (publ) (CALT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Palisade Bio compare to LB Pharmaceuticals?

LB Pharmaceuticals (NASDAQ:LBRX) and Palisade Bio (NASDAQ:PALI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, profitability, analyst recommendations and earnings.

LB Pharmaceuticals' return on equity of -25.92% beat Palisade Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LB Pharmaceuticals	N/A	-25.92%	-24.68%
Palisade Bio	N/A	-33.47%	-31.79%

11.8% of Palisade Bio shares are owned by institutional investors. 5.8% of LB Pharmaceuticals shares are owned by insiders. Comparatively, 0.1% of Palisade Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Palisade Bio has higher revenue and earnings than LB Pharmaceuticals. LB Pharmaceuticals is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LB Pharmaceuticals	N/A	N/A	-$25.20M	-$3.44	N/A
Palisade Bio	$250K	1,115.33	-$16.78M	-$0.48	N/A

In the previous week, Palisade Bio had 8 more articles in the media than LB Pharmaceuticals. MarketBeat recorded 9 mentions for Palisade Bio and 1 mentions for LB Pharmaceuticals. LB Pharmaceuticals' average media sentiment score of 1.67 beat Palisade Bio's score of 0.20 indicating that LB Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LB Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Palisade Bio	1 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

LB Pharmaceuticals currently has a consensus target price of $49.63, indicating a potential upside of 26.63%. Palisade Bio has a consensus target price of $9.83, indicating a potential upside of 514.58%. Given Palisade Bio's stronger consensus rating and higher probable upside, analysts clearly believe Palisade Bio is more favorable than LB Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LB Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Palisade Bio beats LB Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does Palisade Bio compare to Xeris Biopharma?

Xeris Biopharma (NASDAQ:XERS) and Palisade Bio (NASDAQ:PALI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, media sentiment, valuation, risk and analyst recommendations.

42.8% of Xeris Biopharma shares are held by institutional investors. Comparatively, 11.8% of Palisade Bio shares are held by institutional investors. 4.4% of Xeris Biopharma shares are held by insiders. Comparatively, 0.1% of Palisade Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Palisade Bio has a net margin of 0.00% compared to Xeris Biopharma's net margin of -5.12%. Xeris Biopharma's return on equity of 338.21% beat Palisade Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xeris Biopharma	-5.12%	338.21%	3.50%
Palisade Bio	N/A	-33.47%	-31.79%

Xeris Biopharma has a beta of 0.7, indicating that its share price is 30% less volatile than the broader market. Comparatively, Palisade Bio has a beta of 1.53, indicating that its share price is 53% more volatile than the broader market.

Xeris Biopharma currently has a consensus price target of $12.80, suggesting a potential upside of 47.81%. Palisade Bio has a consensus price target of $9.83, suggesting a potential upside of 514.58%. Given Palisade Bio's stronger consensus rating and higher possible upside, analysts clearly believe Palisade Bio is more favorable than Xeris Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Palisade Bio had 6 more articles in the media than Xeris Biopharma. MarketBeat recorded 9 mentions for Palisade Bio and 3 mentions for Xeris Biopharma. Xeris Biopharma's average media sentiment score of 0.68 beat Palisade Bio's score of 0.20 indicating that Xeris Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xeris Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Palisade Bio	1 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Xeris Biopharma has higher revenue and earnings than Palisade Bio. Xeris Biopharma is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xeris Biopharma	$335.41M	4.71	$550K	-$0.11	N/A
Palisade Bio	$250K	1,115.33	-$16.78M	-$0.48	N/A

Summary

Palisade Bio beats Xeris Biopharma on 9 of the 17 factors compared between the two stocks.

How does Palisade Bio compare to Harrow?

Harrow (NASDAQ:HROW) and Palisade Bio (NASDAQ:PALI) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment.

Harrow has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market. Comparatively, Palisade Bio has a beta of 1.53, meaning that its share price is 53% more volatile than the broader market.

In the previous week, Palisade Bio had 8 more articles in the media than Harrow. MarketBeat recorded 9 mentions for Palisade Bio and 1 mentions for Harrow. Palisade Bio's average media sentiment score of 0.20 beat Harrow's score of 0.00 indicating that Palisade Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Harrow	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Palisade Bio	1 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Harrow presently has a consensus target price of $66.71, indicating a potential upside of 98.55%. Palisade Bio has a consensus target price of $9.83, indicating a potential upside of 514.58%. Given Palisade Bio's stronger consensus rating and higher probable upside, analysts clearly believe Palisade Bio is more favorable than Harrow.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harrow	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00

72.8% of Harrow shares are held by institutional investors. Comparatively, 11.8% of Palisade Bio shares are held by institutional investors. 12.8% of Harrow shares are held by insiders. Comparatively, 0.1% of Palisade Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Harrow has higher revenue and earnings than Palisade Bio. Harrow is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harrow	$275.59M	4.57	-$5.14M	-$1.00	N/A
Palisade Bio	$250K	1,115.33	-$16.78M	-$0.48	N/A

Palisade Bio has a net margin of 0.00% compared to Harrow's net margin of -13.51%. Palisade Bio's return on equity of -33.47% beat Harrow's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harrow	-13.51%	-38.00%	-3.37%
Palisade Bio	N/A	-33.47%	-31.79%

Summary

Palisade Bio beats Harrow on 11 of the 17 factors compared between the two stocks.

How does Palisade Bio compare to Seaport Therapeutics?

Palisade Bio (NASDAQ:PALI) and Seaport Therapeutics (NASDAQ:SPTX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.

Seaport Therapeutics' return on equity of 0.00% beat Palisade Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palisade Bio	N/A	-33.47%	-31.79%
Seaport Therapeutics	N/A	N/A	N/A

Palisade Bio currently has a consensus target price of $9.83, indicating a potential upside of 514.58%. Seaport Therapeutics has a consensus target price of $37.33, indicating a potential upside of 75.36%. Given Palisade Bio's stronger consensus rating and higher possible upside, equities research analysts clearly believe Palisade Bio is more favorable than Seaport Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00
Seaport Therapeutics	2 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.36

In the previous week, Palisade Bio had 9 more articles in the media than Seaport Therapeutics. MarketBeat recorded 9 mentions for Palisade Bio and 0 mentions for Seaport Therapeutics. Palisade Bio's average media sentiment score of 0.20 beat Seaport Therapeutics' score of 0.00 indicating that Palisade Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Palisade Bio	Neutral
Seaport Therapeutics	Neutral

11.8% of Palisade Bio shares are owned by institutional investors. 0.1% of Palisade Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Palisade Bio has higher revenue and earnings than Seaport Therapeutics. Palisade Bio is trading at a lower price-to-earnings ratio than Seaport Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palisade Bio	$250K	1,115.33	-$16.78M	-$0.48	N/A
Seaport Therapeutics	N/A	N/A	-$74.88M	-$12.12	N/A

Summary

Palisade Bio beats Seaport Therapeutics on 11 of the 14 factors compared between the two stocks.

How does Palisade Bio compare to Calliditas Therapeutics AB (publ)?

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Palisade Bio (NASDAQ:PALI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations, media sentiment and institutional ownership.

Palisade Bio has lower revenue, but higher earnings than Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A
Palisade Bio	$250K	1,115.33	-$16.78M	-$0.48	N/A

Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market. Comparatively, Palisade Bio has a beta of 1.53, indicating that its stock price is 53% more volatile than the broader market.

Palisade Bio has a consensus target price of $9.83, indicating a potential upside of 514.58%. Given Palisade Bio's stronger consensus rating and higher possible upside, analysts clearly believe Palisade Bio is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00

Palisade Bio has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Palisade Bio's return on equity of -33.47% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%
Palisade Bio	N/A	-33.47%	-31.79%

2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. Comparatively, 11.8% of Palisade Bio shares are held by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are held by insiders. Comparatively, 0.1% of Palisade Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Palisade Bio had 9 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 9 mentions for Palisade Bio and 0 mentions for Calliditas Therapeutics AB (publ). Palisade Bio's average media sentiment score of 0.20 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Palisade Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Calliditas Therapeutics AB (publ)	Neutral
Palisade Bio	Neutral

Summary

Palisade Bio beats Calliditas Therapeutics AB (publ) on 13 of the 17 factors compared between the two stocks.

Get Palisade Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PALI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PALI vs. The Competition

Export

Metric	Palisade Bio	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$294.52M	$12.60B	$7.31B	$13.29B
Dividend Yield	N/A	2.63%	2.52%	12.57%
P/E Ratio	-3.33	792.28	274.08	25.69
Price / Sales	1,115.33	862.22	638.21	78.99
Price / Cash	N/A	88.64	77.80	52.76
Price / Book	1.84	10.59	10.47	6.32
Net Income	-$16.78M	$2.81B	$3.49B	$359.73M
7 Day Performance	-5.88%	-0.11%	-0.67%	0.17%
1 Month Performance	-20.40%	-1.34%	-3.17%	-3.27%
1 Year Performance	133.78%	2.86%	15.14%	5.58%

Palisade Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PALI Palisade Bio	2.7445 of 5 stars	$1.60 -5.3%	$9.83 +514.6%	+153.0%	$294.52M	$250K	N/A	14	News Coverage Analyst Forecast
LBRX LB Pharmaceuticals	2.6628 of 5 stars	$43.04 -4.0%	$49.63 +15.3%	+163.0%	$1.39B	N/A	N/A	27	Positive News
XERS Xeris Biopharma	4.104 of 5 stars	$7.49 -1.1%	$12.80 +70.9%	+9.5%	$1.37B	$291.85M	N/A	435
HROW Harrow	1.7223 of 5 stars	$33.84 -0.7%	$66.38 +96.1%	-31.2%	$1.27B	$275.59M	N/A	373
SPTX Seaport Therapeutics	2.0473 of 5 stars	$22.96 -7.0%	$37.33 +62.6%	N/A	$1.23B	N/A	N/A	58

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PALI) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Palisade Bio (PALI) Competitors

PALI vs. LBRX, XERS, HROW, SPTX, and CALT

How does Palisade Bio compare to LB Pharmaceuticals?

Summary

How does Palisade Bio compare to Xeris Biopharma?

Summary

How does Palisade Bio compare to Harrow?

Summary

How does Palisade Bio compare to Seaport Therapeutics?

Summary

How does Palisade Bio compare to Calliditas Therapeutics AB (publ)?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PALI vs. The Competition

Palisade Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Palisade Bio (PALI) Competitors

PALI vs. LBRX, XERS, HROW, SPTX, and CALT

How does Palisade Bio compare to LB Pharmaceuticals?

Is LBRX or PALI more profitable?

Do insiders and institutionals believe in LBRX or PALI?

Which has stronger earnings & valuation, LBRX or PALI?

Does the media favor LBRX or PALI?

Do analysts recommend LBRX or PALI?

Summary

How does Palisade Bio compare to Xeris Biopharma?

Do institutionals & insiders have more ownership in XERS or PALI?

Is XERS or PALI more profitable?

Which has more risk and volatility, XERS or PALI?

Do analysts prefer XERS or PALI?

Does the media prefer XERS or PALI?

Which has higher earnings & valuation, XERS or PALI?

Summary

How does Palisade Bio compare to Harrow?

Which has more volatility & risk, HROW or PALI?

Does the media refer more to HROW or PALI?

Do analysts rate HROW or PALI?

Do institutionals & insiders believe in HROW or PALI?

Which has preferable earnings and valuation, HROW or PALI?

Is HROW or PALI more profitable?

Summary

How does Palisade Bio compare to Seaport Therapeutics?

Is PALI or SPTX more profitable?

Do analysts rate PALI or SPTX?

Does the media prefer PALI or SPTX?

Do insiders and institutionals believe in PALI or SPTX?

Which has preferable valuation and earnings, PALI or SPTX?

Summary

How does Palisade Bio compare to Calliditas Therapeutics AB (publ)?

Which has higher earnings & valuation, CALT or PALI?

Which has more volatility & risk, CALT or PALI?

Do analysts prefer CALT or PALI?

Is CALT or PALI more profitable?

Do institutionals and insiders believe in CALT or PALI?

Does the media refer more to CALT or PALI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PALI vs. The Competition

Palisade Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools